Liver transplantation
Drug research and approvals for liver transplantation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 195 studies of liver transplantation are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 1 approved and 6 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 195
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 2
Recruiting Now
Newest start dates first, of 195 recruiting on ClinicalTrials.gov ↗- In-situ vs Ex-situ Liver PreservationNCT07899853 · Not applicable · Leiden University Medical Center · starts Nov 4, 2026
- Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes…NCT07665372 · Not applicable · Johns Hopkins University · starts Nov 1, 2026
- Peer Support for Liver Transplant Recipients With History of ALDNCT07397598 · Not applicable · Johns Hopkins University · starts Oct 27, 2026
- Expanding HOPE LiverNCT07778459 · Not reported · National Institute of Allergy and Infectious Diseases (NIAID) · starts Oct 15, 2026
- Study of Sleep Quality and Its Specific Determinants During the Care Pathway of a Liver Transplant PatientNCT07674355 · Not reported · Hospices Civils de Lyon · starts Oct 7, 2026
- TLI- and ATG-Enabled Minimization Protocol in Liver TransplantationNCT07634562 · Phase 1 / Phase 2 · Stanford University · starts Sep 1, 2026
- Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired…NCT07654855 · Not reported · AstraZeneca · starts Sep 1, 2026
- Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)NCT07718126 · Phase 4 · West China Hospital · starts Sep 1, 2026
- Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)NCT07739914 · Phase 3 · Hannover Medical School · starts Aug 19, 2026
- Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille…NCT07335523 · Not reported · Digestive Care, Inc. · starts Aug 3, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Apr 8, 2026 | Expanded antimicrobial prophylaxis to reduce surgical site infections in liver transplant recipientsMEROPENEM / VANCOMYCIN / DAPTOMYCIN / FLUCONAZOLE | UNIVERSITY HEALTH NETWORK | Ongoing |
| Mar 10, 2022 | The glp-1 agonist semaglutide for the treatment of metabolic disease in liver transplant recipients: a phase IV, randomized trialSEMAGLUTIDE/ SITAGLIPTIN | UNIVERSITY HEALTH NETWORK | Pending |
| Feb 24, 2015 | Randomized controlled trial of ex vivo oxygenated, normothermic liver perfusion (organox metra) compared to standard cold storage in clinical liver…SOLUTION TO SUPPORT ORGANOX METRA PERFUSION SYSTEM | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Pending |
| Dec 16, 2014 | A multicenter treatment protocol for daclatasvir (bms-790052) in combination with sofosbuvir for the treatment of post-liver transplant subjects with chronic…DACLATASVIR (BMS-790052)/ SOFOSBUVIR | Bristol-Myers Squibb | Pending |
| Apr 15, 2014 | Assessing the safety and efficacy of a portable ex vivo oxygenated, normothermic liver perfusion system (organox metra) prior to liver transplantationSOLUTION TO SUPPORT ORGANOX METRA PERFUSION SYSTEM | GOVERNORS OF THE UNIVERSITY OF ALBERTA | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Apr 6, 2007 | HepaGam BPrevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients | Cangene Corporation | Approved |
| Mar 6, 2026 | tegoprubartprevention of allograft rejection in liver transplantation | Eledon Pharmaceuticals, Inc. | Designated |
| Feb 15, 2022 | bucillaminePrevention of ischemia-reperfusion injury during liver transplantation | Revive Therapeutics Inc. | Designated |
| May 6, 2013 | hepatitis B virus neutralizing human monoclonal antibodyPrevention of hepatitis B recurrence following liver transplantation | Green Cross Corp. | Designated |
| Jan 10, 2005 | (2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hept…Prevention of acute rejection following kidney, heart, and liver transplantation | Astellas Pharma US, Inc. | Designated |
| Jul 15, 2003 | Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab…For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation | Cubist Pharmaceuticals | Designated |
| Jun 17, 1991 | Monoclonal antibody to hepatitis B virus (human)Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection. | Protein Design Labs, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Dec 8, 2017 | Tacforiustacrolimus · generic | Teva B.V. | EMA ↗ |
| Nov 30, 2009 | Zutectrahuman hepatitis B immunoglobulin | Biotest Pharma GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA